Skandinaviska Enskilda Banken (SEB)
FPRX

Skandinaviska Enskilda Banken (SEB)’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-99,100
Closed -$5.2M – 759
2016
Q3 		$5.2M Buy
+99,100
New +$4.73M 0.06% 249

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s FPRX Position: Q4 2016 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Five Prime Therapeutics, Inc. (FPRX) in Q4 2016, closing a stake of 99,100 shares — an estimated $5.2M sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in FPRX in Q3 2016 and held it in 1 quarter. The position peaked at $5.2M in Q3 2016. 172 funds tracked by Wall St. Rank hold FPRX as of Q4 2016.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Five Prime Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 99,100 Five Prime Therapeutics, Inc. shares in Q4 2016, an estimated $5.2M.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • Skandinaviska Enskilda Banken (SEB)'s Five Prime Therapeutics, Inc. position peaked at $5.2M in Q3 2016.
  • 172 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q4 2016.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2016, filed 14 Feb 2017.